Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scandium-47
- Development stage
- Preclinical
- Lead developer
- ANSTO
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Scandium-47 (47Sc) is a beta-emitting radioisotope being developed as a theranostic agent for targeted cancer therapy. It has a half-life of 3.35 days and emits beta radiation (average energy 162 keV) suitable for therapeutic applications and gamma emissions (159 keV) suitable for SPECT imaging. Scandium-47 is frequently discussed as part of a theranostic pair with scandium-44 or scandium-43 (used for PET imaging), allowing the same chemical targeting agent to be used for both diagnosis and therapy. The radioisotope is typically chelated to targeting molecules, such as peptides or antibodies, using bifunctional chelators like DOTA. It is currently being investigated in preclinical research for the treatment of neuroendocrine tumors, prostate cancer, and other malignancies.
- Other names
- Scandium-47 radioisotopeScandium47 radioisotopeScandium 47 radioisotope
02
Targets
DNA
Beyond the preview
Go deeper on scandium-47.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scandium-47.